From Wikipedia, the free encyclopedia
Canadian pharmacologist (1934–2021)
Philip Seeman
Born (1934-02-08 ) 8 February 1934Died 9 January 2021(2021-01-09) (aged 86) Awards
Order of Canada
Philip Seeman ,
OC
FRSC (8 February 1934 – 9 January 2021) was a Canadian
schizophrenia researcher and
neuropharmacologist , known for his research on
dopamine receptors.
[1]
Career
Born in
Winnipeg ,
Manitoba , Seeman was raised in
Montreal . He received a
Bachelor of Science degree, honours physics & physiology (1955), a
Master of Science degree, physiology of transport & secretion (1956), and a
Doctor of Medicine (1960) from
McGill University . In 1966, he received a Ph.D. in life sciences from
Rockefeller University .
In 1967, Seeman became an assistant professor in the Department of Pharmacology at the
University of Toronto . In 1970, he was appointed a professor.
In 1974, having spent years in search of the binding site of antipsychotic medication, he discovered the
dopamine D2 receptor , the basis for the
dopamine hypothesis of schizophrenia .
[2]
[3]
In 2001, he was made an Officer of the
Order of Canada "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's".
[4]
In 1985, he was made a Fellow of the
Royal Society of Canada .
[5]
He was married to Dr.
Mary V. Seeman .
[6]
Notes
References
Madras, B.K. (2013). "History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia". Journal of the History of the Neurosciences: Basic and Clinical Perspectives . 22 (1): 62–78.
doi :
10.1080/0964704x.2012.678199 .
PMID
23323533 .
S2CID
12002684 .
Seeman, P. (2011).
"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors" . CNS Neuroscience & Therapeutics . 17 (2): 118–132.
doi :
10.1111/j.1755-5949.2010.00162.x .
PMC
6493870 .
PMID
20560996 .
P. Seeman (2010). "Dopamine D2 Receptors as Treatment Targets in Schizophrenia. Clinical Schizophrenia & Related Psychoses April: 56-73.
P. Seeman (2007), Scholarpedia, 2(10): 3634 doi.4249/scholarpedia.3634
Seeman, P. (2006). "Targeting the dopamine D2 receptor in schizophrenia". Expert Opinion on Therapeutic Targets . 10 (4): 515–531.
doi :
10.1517/14728222.10.4.515 .
PMID
16848689 .
S2CID
30902536 .
Seeman, P.; Weinshenker, D.; Quirion, R.; Srivastava, L.; Bhardwaj, S.K.; Grandy, D.K.; Premont, R.; Sotnikova, T.; Boksa, P.; El-Ghundi, M.; O'Dowd, B.F.; George, S.R.; Perreault, M.L.; Mannisto, P.T.; Robinson, S.; Palmiter, R.D.; Tallerico, T. (2005).
"Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis" . Proceedings of the National Academy of Sciences USA . 102 (9): 3513–3518.
Bibcode :
2005PNAS..102.3513S .
doi :
10.1073/pnas.0409766102 .
PMC
548961 .
PMID
15716360 .
Seeman, P.; Chau-Wong, M.; Tedesco, J.; Wong, K. (1975).
"Brain receptors for antipsychotic drugs and dopamine: Direct binding assays" . Proceedings of the National Academy of Sciences, USA . 72 (11): 4376–4380.
Bibcode :
1975PNAS...72.4376S .
doi :
10.1073/pnas.72.11.4376 .
PMC
388724 .
PMID
1060115 .
External links